The Oncolytic Virus Immunotherapy Market will witness a CAGR of 12% by reaching ~ US$ 214 Million from 2019 to 2029. The new-fangled healthcare electronic technologies like 3D printing, GPS tracking, and wearable biometric devices are being tested concerning clinical use. Cutting-edge technology is expected to be one of the driving forces in the healthcare industry in the subsequent decade.

The new study report by Persistence Market Research (PMR) reveals that the oncolytic virus immunotherapy market value is all set to reach US$ ~67 Mn, by 2019-end. As per the PMR’s report, the oncolytic virus immunotherapy market is estimated to grow at a CAGR of ~12% over the period of assessment, 2019-2029.

Increasing adoption of adjuvant therapy in developed economies has been fueling the demand for new treatments such as oncolytic virus immunotherapy. For instance, the launch of first FDA approved oncolytic virus, IMLYGIC™ (talimogene laherparepvec) by the leading pharmaceutical manufacturer Amgen has offered oncologists and patients a wider and more targeted treatment approach for overcoming cancer. Amgen’s IMLYGIC™ remains the only FDA approved oncolytic virus immunotherapy drug that is prescribed for melanoma cancer.

Strategizing The Moves For The Next Decade? See Through Sample Of Oncolytic Virus Immunotherapy Market Report! https://www.persistencemarketresearch.co/samples/15262

Company Profiles:

  • BioVex, Inc. (Amgen, Inc.)
  • Cold Genesys, Inc.
  • DNAtrix Therapeutics
  • Genelux Corporation
  • Lokon Pharma AB
  • Oncolytics Biotech, Inc.
  • ORYX GmbH & Co. KG
  • PsiOxus Therapeutics
  • SillaJen, Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio
  • Targovax ASA
  • Transgene sa
  • Turnstone Biologics
  • VCN Biosciences
  • Viralytics Ltd. (Merck & Co., Inc.)
  • Vyriad
  • Shanghai Sunway Biotech

Favorable reimbursement for oncolytic virus immunotherapy is poised to offer new growth opportunities for the market players. Additionally, Affordable Care Act in the U.S. is paving the way for successfully increasing insurance coverage for cancer treatment, and the result is likely to lead to increased demand for oncological therapies.

Such factor along with several favorable policies for cancer treatment is anticipated to contribute immensely towards the growth of the oncolytic virus immunotherapy industry during the forecast period.

Growing Prevalence of Metastatic Cancer Bringing in Massive Competition in the Oncolytic Virus Immunotherapy Landscape

According to PMR, growing prevalence of metastatic cancer and rising demand for adjuvant therapy drugs and cancer relapses during cancer treatment have created opportunities for key market players to come up with oncolytic virus immunotherapy products at competitive rates by combining new viruses.

Starting With The New Decade On A Diligent Note In The Oncolytic Virus Immunotherapy Market? https://www.persistencemarketresearch.co/methodology/15262

Apart from the top global market players such as BioVex, Inc. (Amgen, Inc.) and Shanghai Sunway Biotech Co. Ltd. (China), there are several other players in the regional oncolytic virus immunotherapy market that are constantly focusing on discovering new drug candidates in oncolytic virus immunotherapy.

Most of the drugs in the pipeline are in various stages of clinical trials awaiting market approvals. For example, oncolytic viruses from Transgene/Sillajen, Oncolytic Biotech and other players are in the late phase III stage of clinical trials, and are expected to enter the oncolytic virus immunotherapy market in the coming years.

According to the PMR’s report, the adoption of oncolytic virus immunotherapy in hospitals will continue to account for relatively high market share, while stakeholders are targeted towards capitalizing on specialty clinics. A significant rise in demand for oncolytic virus immunotherapy drugs in developed countries will further work to the advantage of the market players.

A remarkable shift has been observed in the new drug development and product launch in cancer treatment drugs as the blockbuster drug model is dead.

Key players are now adopting new strategies to develop adjuvant therapies and supportive therapies that can help irradiate cancer at the maximum level, such as oncolytic virus immunotherapy combined with chemotherapy. Such developmental trends are likely to remain instrumental to the growth of the oncolytic virus immunotherapy market.

How About Obtaining Insights About The Region To Enter Concerning The Oncolytic Virus Immunotherapy Market? Press The “Purchase Now” Button To Have Our Oncolytic Virus Immunotherapy Market Report! https://www.persistencemarketresearch.com/checkout/15262

Increasing Immunotherapy Research Will Offer New Growth Prospects

According to the PMR study, increasing importance of R&D in oncology medicines and immunotherapies for cancers such as colorectal, lung, multiple myeloma, prostate, and melanoma is expected to create immense growth opportunities for the oncolytic virus immunotherapy market.

Besides this, collaborations among the key players in the pharmaceutical industry, funding programs and reimbursement policies to meet the unmet diagnostic and treatment needs of the patients suffering from life-threatening diseases such as cancer are also expected to fuel the growth of the oncolytic virus immunotherapy market.

Growing interest of biopharmaceutical industries in the development of biologics for various cancers, will further expand the pipeline for the treatment of cancer. Various major players are concentrating on the research for the available treatment and development of specific oncolytic virus for cancer, which will boost the market for oncolytic virus immunotherapy during the forecast period.

Further, growing acceptance of oncolytic drugs among patient pool is also high due to treatment effectiveness of the medication. Hence, companies operating in oncolytic virus immunotherapy are expected to mostly derive profit from the development of adoptive immune viruses.

The funding for cancer research and investments in cancer therapy and oncolytic virus immunotherapy have increased, which has increased the number of personnel employed and projects undertaken. The major sources of research and development spending include governments, private funding, venture capitalists or commercial organizations.

Access Related Reports:

Crow’s Feet Market:

As per Persistence Market Research’s analysis report, the global market for crow’s feet is estimated to reach a value of over US$ 800 Mn by the end of the year of assessment (2026), with the demand for the treatment to grow at a steady pace in the coming years. 

Bile Duct Cancer Treatment Market:

Increased industrialization is also attributing to the growth in the APAC bile duct cancer treatment market as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India. Persistence Market Research’s new study on the global bile duct cancer treatment market reveals that by the end of 2025, APAC region will procure a global revenue share of over 45%.

Meningococcal Vaccine Market:                    

Constant research and development in meningococcal vaccines for various meningococcal disease preventive applications, coupled with the sanctions of subsidy & support of government organizations for immunization program are among the significant factors that are anticipated to drive the growth of the meningococcal vaccine market during the forecast period.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

 

Tags: Global Oncolytic Virus Immunotherapy Forecast To 2025, Oncolytic Virus Immunotherapy Market Key Players, Global Oncolytic Virus Immunotherapy Challenges, Global Oncolytic Virus Immunotherapy Scenario, Oncolytic Virus Immunotherapy Future Opportunities, Global Oncolytic Virus Immunotherapy Covid-19 Impact Analysis

See Campaign: https://www.persistencemarketresearch.com/market-research/oncolytic-virus-immunotherapy-market.asp
Contact Information:
Persistence Market Research Address – 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353

Tags:
Menafn, PR-Wirein, Reportedtimes, Extended Distribution, iCN Internal Distribution, Research Newswire, English